FDA
-
-
-
-
-
-
-
Fractyl Health completes enrollment in weight maintenance study
-
-
-
-
-
-
-
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
-
-
-
-
-
-
-
Fractyl Health prices $20 million public offering at $1.05 per share
-
-
-
-
-
-
-
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
-
-
-
-
-
-
-
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
-
-
-
-
-
-
-
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

